Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
AIB1 / SRC-3 Polyclonal Antibody, Active Motif™
Rabbit Polyclonal Antibody
Supplier: Active Motif 39798
Description
AIB1-AC3 recognizes AIB1, a member of the SRC-1 family of nuclear receptor coactivators with an apparent molecular weight of 160kDa. The AIB1 gene has been mapped to region 20q12 and has been shown to be amplified in breast tumors and pancreatic cancer cell lines. AIB1 interacts in a ligand-dependent fashion with the estrogen receptor to enhance estrogen-dependent transcriptional gene activation.Specifications
AIB1 / SRC-3 | |
Polyclonal | |
Unconjugated | |
NCOA3 | |
2010305B15Rik; ACTR; AIB1; AIB-1; Amplified in breast cancer 1 protein; amplified in breast cancer-1 protein homolog; AW321064; BHLHE42; CAGH16; CBP-interacting protein; Class E basic helix-loop-helix protein 42; CTG26; KAT13B; MGC141848; NCOA3; NCoA-3; Nuclear receptor coactivator 3; OTTHUMP00000031716; p/Cip; pCIP; RAC3; RAC-3; Receptor-associated coactivator 3; RP5-1049G16.3; Src3; SRC-3; Steroid receptor coactivator protein 3; Thyroid hormone receptor activator molecule 1; TNRC14; TNRC16; TRAM1; TRAM-1 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
8202 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
ChIP Assay, Western Blot | |
Lot-Specific | |
70mM tris with 0.07mM EDTA, 105mM NaCl, 30% glycerol, 31mM glycine and 0.035% sodium azide; pH 8 | |
Q9Y6Q9 | |
NCOA3 | |
This AIB1 antibody was raised against a peptide derived from human AIB1/SRC-3. | |
10 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Provide Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction